Brokers Offer Predictions for Haemonetics Co.’s FY2026 Earnings (NYSE:HAE)

Haemonetics Co. (NYSE:HAE) – Investment analysts at Barrington Research reduced their FY2026 EPS estimates for shares of Haemonetics in a research report issued to clients and investors on Friday, April 12th. Barrington Research analyst M. Petusky now forecasts that the medical instruments supplier will earn $4.80 per share for the year, down from their prior forecast of $4.85. Barrington Research currently has a “Outperform” rating and a $105.00 target price on the stock. The consensus estimate for Haemonetics’ current full-year earnings is $3.95 per share. Barrington Research also issued estimates for Haemonetics’ FY2027 earnings at $5.52 EPS.

Haemonetics (NYSE:HAE) last released its quarterly earnings data on Thursday, February 8th. The medical instruments supplier reported $1.04 EPS for the quarter, topping the consensus estimate of $0.94 by $0.10. Haemonetics had a net margin of 9.97% and a return on equity of 22.37%. The business had revenue of $336.20 million for the quarter, compared to analyst estimates of $320.84 million. During the same period in the previous year, the firm earned $0.85 EPS. The business’s revenue for the quarter was up 10.1% compared to the same quarter last year.

Other research analysts have also issued reports about the stock. StockNews.com lowered shares of Haemonetics from a “buy” rating to a “hold” rating in a report on Friday, March 22nd. TheStreet lowered shares of Haemonetics from a “b-” rating to a “c+” rating in a report on Thursday, February 29th.

Haemonetics Price Performance

Haemonetics stock opened at $85.22 on Monday. Haemonetics has a 52 week low of $70.74 and a 52 week high of $95.26. The company has a quick ratio of 1.76, a current ratio of 2.92 and a debt-to-equity ratio of 0.91. The firm’s 50-day simple moving average is $78.23 and its 200 day simple moving average is $82.84. The firm has a market capitalization of $4.33 billion, a PE ratio of 34.64, a P/E/G ratio of 2.01 and a beta of 0.36.

Institutional Trading of Haemonetics

A number of hedge funds and other institutional investors have recently made changes to their positions in the stock. Stifel Financial Corp increased its stake in shares of Haemonetics by 2.5% in the first quarter. Stifel Financial Corp now owns 4,891 shares of the medical instruments supplier’s stock worth $405,000 after buying an additional 119 shares during the last quarter. Knights of Columbus Asset Advisors LLC increased its stake in shares of Haemonetics by 1.3% in the third quarter. Knights of Columbus Asset Advisors LLC now owns 10,005 shares of the medical instruments supplier’s stock worth $896,000 after buying an additional 128 shares during the last quarter. Meeder Asset Management Inc. increased its stake in shares of Haemonetics by 65.2% in the fourth quarter. Meeder Asset Management Inc. now owns 342 shares of the medical instruments supplier’s stock worth $27,000 after buying an additional 135 shares during the last quarter. Metropolitan Life Insurance Co NY increased its stake in shares of Haemonetics by 4.5% in the fourth quarter. Metropolitan Life Insurance Co NY now owns 3,202 shares of the medical instruments supplier’s stock worth $252,000 after buying an additional 138 shares during the last quarter. Finally, Parkside Financial Bank & Trust increased its stake in shares of Haemonetics by 21.7% in the second quarter. Parkside Financial Bank & Trust now owns 786 shares of the medical instruments supplier’s stock worth $67,000 after buying an additional 140 shares during the last quarter. Institutional investors own 99.67% of the company’s stock.

Haemonetics Company Profile

Haemonetics Corporation, a healthcare company, provides suite of medical products and solutions in the United States and internationally. The company offers automated plasma collection systems, donor management software, and supporting software solutions including NexSys PCS and PCS2 plasmapheresis equipment and related disposables and intravenous solutions, as well as integrated information technology platforms for plasma customers to manage their donors, operations, and supply chain; and NexLynk DMS donor management system, and Donor360.